MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$6,043K
Free Cash flow
-$6,043K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Share-based compensation
Prepaid expenses and other curre...
Accrued expenses and other liabi...
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable
Research and development incenti...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-7,005
-6,719
-7,351
-7,024
Share-based compensation
1,317
1,605
1,543
1,712
Depreciation
38
44
36
39
Amortization of intangible assets
127
127
424
-183
Amortization of operating lease right-of-use assets
134
134
132
133
Change in fair value of warrants
-6
-17
-294
-196
Non-cash interest income
19
31
70
34
Non-cash interest expense
7
12
18
17
Foreign currency transaction gain/(loss)
-361
1,628
-126
1,873
Other income
-
-
0
300
Non-cash consideration, milestone payment
-
-
0
-
Prepaid expenses and other current assets
-681
-271
-235
164
Research and development incentives receivable
119
95
473
-1,661
Accounts payable
-2,137
1,957
447
-236
Accrued expenses and other liabilities
577
229
-2,261
-673
Operating lease liabilities
1
-201
-194
-188
Net cash used in operating activities
-6,043
-4,312
-7,682
-7,309
Payments for intangible assets
0
300
0
0
Purchase of property and equipment
0
0
0
0
Proceeds from out-licensing
-
-
0
300
Net cash used in investing activities
0
-300
0
300
Proceeds from exercise of warrants
0
0
0
0
Proceeds from issuance of ordinary shares
-
-
39
0
Transaction costs on issuance of ordinary shares
0
0
0
0
Net cash provided by financing activities
0
0
39
0
Decrease in cash and cash equivalents
-6,043
-4,612
-7,643
-7,009
Cash and cash equivalents at january 1,
36,223
40,992
48,698
69,802
Effect of exchange rate changes
-62
-157
-63
1,917
Cash and cash equivalents at june 30,
30,118
36,223
40,992
48,698
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Decrease in cash and cash
equivalents
-$6,043K
(62.26%↑ Y/Y)
Share-based compensation
$1,317K
(-69.68%↓ Y/Y)
Prepaid expenses and
other current assets
-$681K
(-539.35%↓ Y/Y)
Accrued expenses and
other liabilities
$577K
(6.85%↑ Y/Y)
Foreign currency
transaction gain/(loss)
-$361K
(95.54%↑ Y/Y)
Amortization of operating
lease right-of-use...
$134K
(-48.85%↓ Y/Y)
Amortization of intangible
assets
$127K
(-43.30%↓ Y/Y)
Depreciation
$38K
(-53.66%↓ Y/Y)
Non-cash interest
expense
$7K
(-96.37%↓ Y/Y)
Operating lease
liabilities
$1K
(100.28%↑ Y/Y)
Net cash used in
operating activities
-$6,043K
(62.18%↑ Y/Y)
Canceled cashflow
$3,243K
Net loss
-$7,005K
(74.53%↑ Y/Y)
Accounts payable
-$2,137K
(-34.49%↓ Y/Y)
Research and development
incentives receivable
$119K
(157.21%↑ Y/Y)
Non-cash interest income
$19K
Change in fair value of
warrants
-$6K
(98.10%↑ Y/Y)
Buy us a coffee
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)